J
Jedd D. Wolchok
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 795
Citations - 154490
Jedd D. Wolchok is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ipilimumab & Immune system. The author has an hindex of 140, co-authored 713 publications receiving 123336 citations. Previous affiliations of Jedd D. Wolchok include Ludwig Institute for Cancer Research & University of York.
Papers
More filters
Posted ContentDOI
In vivo optical imaging-guided targeted sampling for precise diagnosis and molecular pathology.
Aditi Sahu,Yuna Oh,Gary Peterson,Miguel Cordova,Cristian Navarrete-Dechent,Cristian Navarrete-Dechent,Melissa Gill,Melissa Gill,Christi Alessi-Fox,Salvador González,William Phillips,Steven Wilson,Reza Afzalneia,Raven Rose,Abu-Akeel Mohsen,Danielle M. Bello,Ashfaq A. Marghoob,Anthony M. Rossi,Jedd D. Wolchok,Taha Merghoub,Veronica Rotemberg,Chih-Shan Jason Chen,Milind Rajadhyaksha +22 more
TL;DR: In this article, the authors explored the feasibility of performing 1-2mm precision biopsies guided by high-resolution reflectance confocal microscopy (RCM) and optical coherence tomography (OCT), and reflective metallic grids for accurate spatial targeting.
Journal ArticleDOI
Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets).
James J. Harding,Federica Catalanotti,Amin Yaqubie,Gregory McDermott,Romona Kersellius,Taha Merghoub,Richard D. Carvajal,Sandra P. D'Angelo,Mark A. Dickson,Gary K. Schwartz,Jedd D. Wolchok,Michael F. Berger,David B. Solit,Paul B. Chapman +13 more
TL;DR: A large number of pts with BRAF-mutant melanoma treated with VEM had active brain mets and the best overall response rate (BORR) and, when applicable, the overrall intracranial response rates (OIRR) by RECIST v1.1, progression-free survival (PFS), and overall survival (OS) to RAF inhibition were determined.
Journal ArticleDOI
Development of effective vaccines for old mice in a tumor model.
David N. Posnett,Manuel E. Engelhorn,Yun Lin,Taha Merghoub,Fei Duan,Jedd D. Wolchok,Alan N. Houghton +6 more
TL;DR: This work used DNA tumor antigen vaccines against melanoma and showed that old mice were not protected, and vaccines incorporating fusions of the tumor antigen with microbial adjuvant proteins OmpA or Vp22 dramatically improved protection of old mice.
BookDOI
General Principles of Tumor Immunotherapy
TL;DR: What do you do to start reading general principles of tumor immunotherapy?
Proceedings ArticleDOI
Abstract 2855: Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma
Walter J. Urba,Salvador Martín-Algarra,Margaret K. Callahan,Jedd D. Wolchok,William H. Sharfman,Jeffrey A. Sosman,Shailender Bhatia,Wen-Jen Hwu,Thomas F. Gajewski,Craig L. Slingluff,Yun Shen,Christine Horak,F. Stephen Hodi +12 more
TL;DR: Nivolumab monotherapy is marked by increased TIL, inclusive of cytotoxic CD8 T cells, and FOXP3+ T regulatory cells and these increases are associated with response.